Comparative Pharmacology
Head-to-head clinical analysis: DEXTENZA versus TEXACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTENZA versus TEXACORT.
DEXTENZA vs TEXACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a corticosteroid with glucocorticoid activity that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as prostaglandins and leukotrienes, and suppression of immune cell migration and activation.
TEXACORT (hydrocortisone) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, immunosuppressive, and metabolic effects.
Insert 0.4 mg intracanalicularly (into the lacrimal punctum) as a single dose; releases dexamethasone over 30 days.
50 mg intravenously every 6 hours as a single agent or in combination with other antineoplastic agents.
None Documented
None Documented
The terminal elimination half-life of dexamethasone from plasma after systemic absorption is approximately 3-4 hours. However, Dextenza provides sustained local delivery to the ocular surface; the insert releases dexamethasone over 30 days, with therapeutic levels maintained throughout.
Terminal elimination half-life: 3-4 hours. In renal impairment, half-life may be prolonged up to 12 hours.
Dextenza (dexamethasone ophthalmic insert) is administered intracanalicularly; systemic absorption is minimal. Following release into the tear film, the drug is primarily eliminated via nasolacrimal drainage and subsequent gastrointestinal absorption with hepatic metabolism. Renal excretion accounts for <5% of the dose as unchanged drug; biliary/fecal elimination is negligible.
Renal: 80-90% as unchanged drug and inactive metabolites; biliary/fecal: 10-20%.
Category C
Category C
Corticosteroid
Corticosteroid